TG103
TG103 is an experimental GLP-1 receptor agonist and Fc fusion protein combination, developed by CSPC Pharmaceutical Group.[1]
References
[edit]- ^ Jin, Jiangli; Cui, Gang; Mi, Na; Wu, Wei; Zhang, Xin; Xiao, Chunyan; Wang, Jing; Qiu, Xueying; Han, Mai; Li, Ziyan; Wang, Lei; Lu, Tong; Niu, Huikun; Wu, Zhaoxi; Li, Jintong (1 June 2023). "Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects". European Journal of Pharmaceutical Sciences. 185: 106448. doi:10.1016/j.ejps.2023.106448. PMID 37062422. S2CID 258166248.